Previous 10 | Next 10 |
SUNNYVALE, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) third quarter after the market clos...
If you’re a traditional investor, you’ve probably heard the saying “invest in what you know.” This is a very basic strategy in the stock market today that entails buying shares of companies you use frequently. Do you drink Starbucks coffee every day? Why ...
GSK extends exclusive target discovery period of collaboration for a fifth year to discover and validate novel drug targets using 23andMe’s proprietary genetic and health survey database 23andMe elects for royalty option as GSK advances immuno-oncology antibody coll...
SUNNYVALE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today received FDA clearance for a genetic health risk report on a hereditary prostate cancer marker. This is the Company&...
23ME-00610 targets CD200R1, an important regulator of T cells and myeloid cells CD200R1 was identified as a promising immuno-oncology target through 23andMe’s proprietary genetic and health survey database Company will host a virtual R&D Day event on January 1...
SUNNYVALE, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the results of the completed redemption (the “Redemption”) of all of its outstanding warrants (the...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
The Nasdaq Biotechnology Index will have a new look on December 20, before the market opens when 129 securities will be added and 21 securities will be deleted as part of the annual reconstitution. Notable additions to the index: Viatris (NASDAQ:VTRS), NovoCure (NASDAQ:NVCR), Anavex Life Scie...
All investors should develop some sort of mental checklist when picking stocks to buy. I personally look for companies with a large and growing addressable market, strong revenue growth, and a business that can scale into more profitability over time. But the bullet point from my investing ...
Shares of 23andMe (NASDAQ: ME) dropped 29.1% in November, according to data from S&P Global Market Intelligence . The DNA testing and therapeutics company reported a disappointing quarterly report and likely fell victim to the sell-off in high-growth names last month. On...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial resu...
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced a new study to help advance research in lung cancer. The focus of the Lun...